- Home
- TSHA
as 02-21-2025 4:00pm EST
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Upcoming Earnings Alert:
Get ready for potential market movements as Taysha Gene Therapies Inc. TSHA prepares to release earnings report on 26 Feb 2025.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 334.1M | IPO Year: | 2020 |
| Target Price: | $6.63 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.19 - $4.32 | Next Earning Date: | 02-26-2025 |
| Revenue: | $9,915,000 | Revenue Growth: | -30.90% |
| Revenue Growth (this year): | -45.49% | Revenue Growth (next year): | -39.74% |
Latest Taysha Gene Therapies Inc. News
TSHA Breaking Stock News: Dive into TSHA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
GlobeNewswire
15 days ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
17 days ago
Scienjoy Holding Leads Our 3 US Penny Stocks To Consider
Simply Wall St.
2 months ago
Acelyrin Leads The Charge With 2 Other US Penny Stocks
GlobeNewswire
2 months ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3 months ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
3 months ago
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Thomson Reuters StreetEvents
3 months ago
Q3 2024 Taysha Gene Therapies Inc Earnings Call
Compare TSHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSHA Taysha Gene Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.